{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Novel+Coronavirus+Pneumonia&page=43", "query": { "condition": "Novel Coronavirus Pneumonia", "page": 43 }, "page_size": 10 }, "pagination": { "page": 43, "page_size": 10, "total_count": 1043, "total_pages": 105, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Novel+Coronavirus+Pneumonia&page=44&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Novel+Coronavirus+Pneumonia&page=42&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-03T05:16:49.473Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05931497", "title": "Sauna for Long Covid", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Long COVID" ], "interventions": [ { "name": "whole body hyperthermia", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 21, "start_date": "2026-08-01", "completion_date": "2026-12-01", "has_results": false, "last_update_posted_date": "2025-11-13", "last_synced_at": "2026-11-03T05:16:49.473Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05931497" }, { "nct_id": "NCT04516746", "title": "Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "COVID-19", "SARS-CoV-2" ], "interventions": [ { "name": "AZD1222", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 32450, "start_date": "2020-08-28", "completion_date": "2023-02-10", "has_results": true, "last_update_posted_date": "2024-02-05", "last_synced_at": "2026-11-03T05:16:49.473Z", "location_count": 78, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 66 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Berkeley", "state": "California" }, { "city": "El Centro", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04516746" }, { "nct_id": "NCT04368988", "title": "Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With/Without Matrix-M Adjuvant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "COVID-19" ], "interventions": [ { "name": "SARS-CoV-2 rS - Phase 1", "type": "BIOLOGICAL" }, { "name": "SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 1", "type": "BIOLOGICAL" }, { "name": "Normal saline solution (NSS), Placebo - Phase 1", "type": "OTHER" }, { "name": "Normal saline solution (NSS), Placebo - Phase 2", "type": "OTHER" }, { "name": "SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 1", "type": "BIOLOGICAL" }, { "name": "Normal saline solution (NSS), Placebo, Day 21 - Phase 1", "type": "OTHER" }, { "name": "SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 2", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Novavax", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "84 Years", "sex": "ALL", "summary": "18 Years to 84 Years" }, "enrollment_count": 1419, "start_date": "2020-05-25", "completion_date": "2022-06-01", "has_results": false, "last_update_posted_date": "2023-04-10", "last_synced_at": "2026-11-03T05:16:49.473Z", "location_count": 8, "location_summary": "Savannah, Georgia • Meridian, Idaho • Newton, Kansas + 5 more", "locations": [ { "city": "Savannah", "state": "Georgia" }, { "city": "Meridian", "state": "Idaho" }, { "city": "Newton", "state": "Kansas" }, { "city": "Wichita", "state": "Kansas" }, { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT04368988" }, { "nct_id": "NCT04707664", "title": "Sargramostim Use in COVID-19 to Recover Patient Health", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Covid19", "SARS-CoV Infection" ], "interventions": [ { "name": "Sargramostim", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Partner Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 600, "start_date": "2021-04-27", "completion_date": "2022-01-31", "has_results": true, "last_update_posted_date": "2023-02-06", "last_synced_at": "2026-11-03T05:16:49.473Z", "location_count": 34, "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Canoga Park, California + 30 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Canoga Park", "state": "California" }, { "city": "Colton", "state": "California" }, { "city": "Bradenton", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04707664" }, { "nct_id": "NCT04336332", "title": "Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "SARS-CoV-2", "COVID-19" ], "interventions": [ { "name": "Hydroxychloroquine Sulfate + Azithromycin", "type": "COMBINATION_PRODUCT" }, { "name": "Hydroxychloroquine Sulfate", "type": "DRUG" } ], "intervention_types": [ "COMBINATION_PRODUCT", "DRUG" ], "sponsor": "Rutgers, The State University of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 75, "start_date": "2020-04-01", "completion_date": "2020-10-14", "has_results": true, "last_update_posted_date": "2023-02-28", "last_synced_at": "2026-11-03T05:16:49.473Z", "location_count": 5, "location_summary": "Livingston, New Jersey • New Brunswick, New Jersey • Newark, New Jersey", "locations": [ { "city": "Livingston", "state": "New Jersey" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "Newark", "state": "New Jersey" }, { "city": "Newark", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT04336332" }, { "nct_id": "NCT05780541", "title": "PF-07304814 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "COVID-19" ], "interventions": [ { "name": "PF-07304814", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Remdesivir", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 58, "start_date": "2021-09-15", "completion_date": "2023-07-14", "has_results": true, "last_update_posted_date": "2024-02-09", "last_synced_at": "2026-11-03T05:16:49.473Z", "location_count": 31, "location_summary": "Chula Vista, California • Los Angeles, California • Mather, California + 23 more", "locations": [ { "city": "Chula Vista", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Mather", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05780541" }, { "nct_id": "NCT05690503", "title": "Glutamatergic Modulation as a Treatment for Depressive Symptoms Among Patients With Post-acute Sequelae of COVID (PASC): A Pilot Trial", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Post-acute Sequelae of COVID-19", "Depressive Symptoms", "Cognitive Dysfunction" ], "interventions": [ { "name": "CI-581a", "type": "DRUG" }, { "name": "CI-581b", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "New York State Psychiatric Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 12, "start_date": "2023-03-20", "completion_date": "2025-12-31", "has_results": false, "last_update_posted_date": "2024-07-16", "last_synced_at": "2026-11-03T05:16:49.473Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05690503" }, { "nct_id": "NCT04425629", "title": "Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "COVID-19" ], "interventions": [ { "name": "casirivimab+imdevimab combination therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 10078, "start_date": "2020-06-16", "completion_date": "2022-06-09", "has_results": true, "last_update_posted_date": "2023-12-21", "last_synced_at": "2026-11-03T05:16:49.473Z", "location_count": 102, "location_summary": "Mesa, Arizona • Tucson, Arizona • Canoga Park, California + 71 more", "locations": [ { "city": "Mesa", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Canoga Park", "state": "California" }, { "city": "La Mesa", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04425629" }, { "nct_id": "NCT07051031", "title": "COVID-19 Reactogenicity", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "COVID-19" ], "interventions": [ { "name": "Nuvaxovid (NVX-CoV2705)", "type": "DRUG" }, { "name": "mNEXSPIKE mRNA-1283", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Marcel Curlin", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1000, "start_date": "2025-10-01", "completion_date": "2026-06-14", "has_results": false, "last_update_posted_date": "2026-03-04", "last_synced_at": "2026-11-03T05:16:49.473Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT07051031" }, { "nct_id": "NCT04750629", "title": "Clinical Evaluation of a Point-of-Care (POC), COVID-19 Rapid Antigen Test (CoviDx™)", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "SARS-CoV-2", "Covid19" ], "interventions": [ { "name": "POC CoviDx™ Rapid Antigen Test", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Lumos Diagnostics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": null, "sex": "ALL", "summary": "1 Year and older" }, "enrollment_count": 140, "start_date": "2021-02-08", "completion_date": "2021-05-14", "has_results": false, "last_update_posted_date": "2021-06-18", "last_synced_at": "2026-11-03T05:16:49.473Z", "location_count": 2, "location_summary": "Hialeah, Florida • West Palm Beach, Florida", "locations": [ { "city": "Hialeah", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04750629" } ] }